Pharmaceutical - Kalydeco


Current filters:


Popular Filters

Report: Global cystic fibrosis market value to treble by 2019


The global cystic fibrosis market value in seven major countries will jump from $1.2 billion in 2013…

CanadaEuropeKalydecoMarkets & MarketingPharmaceuticalResearchRespiratory and PulmonaryUSAVertex

Vertex reports fifth consecutive quarter of losses; updates on Kalydeco


US biotech firm Vertex Pharmaceuticals (Nasdaq: VRTX) has reported second quarter revenues of $311 million,…

FinancialIncivekIncivoKalydecoNorth AmericaPharmaceuticalVertex

Vertex receives first two Breakthrough Therapy Designations from US FDA


During its presentation at the JP Morgan annual health care conference, US drugmaker Vertex Pharmaceuticals…

KalydecoNorth AmericaPharmaceuticalRare diseasesRegulationVertexVX-809

Vertex' hep C drug Incivek to carry boxed warning in USA; UK to fund Kalydeco


US drugmaker Vertex Pharmaceuticals (Nasdaq: VRTX) says that the label on its new hepatitis C drug Incivek…

Anti-viralsEuropeIncivekKalydecoNorth AmericaPharmaceuticalRare diseasesRegulationVertex

Health Canada approves Vertex' Kalydeco; and Sanofi Pasteur's Menactra


Vertex Pharmaceuticals (Nasdaq: VRTX) says that Health Canada has approved Kalydeco (ivacaftor), the…

BiotechnologyKalydecoMenactraNorth AmericaPharmaceuticalRare diseasesRegulationSanofiSanofi PasteurVaccinesVertex

Canadian scientists' insights into Kalydeco for a rare form of cystic fibrosis


Scientists at the Hospital for Sick Children in Toronto, Canada, have established that a drug recently…

KalydecoPharmaceuticalRare diseasesResearchRespiratory and PulmonaryVertexVX-770

FDA warns on possible cataract risk with Vertex' Kalydeco


The US Food and Drug Administration this week notified health care professionals, parents/caregivers…

KalydecoNorth AmericaPharmaceuticalRare diseasesRegulationVertex

EU approval for Eisai's epilepsy drug Fycompa and Vertex' Kalydeco


Japanese drug major Eisai (TYO: 4523) says that the European Commission has approved for marketing its…

EisaiEuropeFycompaKalydecoNeurologicalPharmaceuticalRare diseasesRegulationVertex

Vertex tumbles despite good final data on combo cystic fibrosis therapy


USA-based Vertex Pharmaceuticals (Nasdaq: VRTX) saw its shares tumble 16% to $51.18 last week, after…

KalydecoPharmaceuticalRare diseasesResearchRespiratory and PulmonaryVertexVX-809

Vertex slumps as firm revises Kalydeco data


The USA's Vertex Pharmaceuticals (Nasdaq: VRTX) saw its shares plunge 19% to $52.85 in early trading…

KalydecoPharmaceuticalRare diseasesResearchRespiratory and PulmonaryVertex

EMA recommends approval of Vertex' CF drug Kalydeco


European Medicines Agency last Friday recommended approval of Kalydeco (ivacaftor), an orphan-designated…

EuropeKalydecoPharmaceuticalRare diseasesRegulationRespiratory and PulmonaryVertex

FDA approves combo diabetes drug Jentadueto and Kalydeco


The US Food and Drug Administration) has approved Jentadueto (linagliptin/metformin hydrochloride) tablets,…

Boehringer IngelheimDiabetesEli LillyJentaduetoKalydecolinagliptinNorth AmericaPharmaceuticalRare diseasesRegulationVertex

Vertex plans for Kalydeco launch


US drugmaker Vertex Pharmaceuticals (Nasdaq: VRTX) announced its 2012 business objectives in conjunction…

Anti-viralsIncivekKalydecoPharmaceuticalRare diseasesRegulationResearchVertex

Vertex updates on US and EU Kalydeco filings; to get new CEO


US drugmaker Vertex Pharmaceuticals (Nasdaq: VRTX) says that the US Food and Drug Administration has…

EuropeKalydecoManagementNorth AmericaPharmaceuticalRare diseasesRegulationVertex

Vertex’ Kalydeco marks a milestone in fight against cystic fibrosis


The oral drug ivacaftor (VX-770) provides major, sustained improvement in lung function, growth and other…

ivacaftorKalydecoPharmaceuticalRare diseasesResearchRespiratory and PulmonaryVertex

Vertex files for US priority review and approval of Kalydeco for cystic fibrosis


USA-based Vertex Pharmaceuticals (Nasdaq: VRTX) says it has filed a New Drug Application with the Food…

KalydecoNorth AmericaPharmaceuticalRare diseasesRegulationVertex

Company Spotlight



Back to top